The global phase III trial, CodeBreak 200 (NCT04303780), comparing sotorasib with docetaxel in patients with mt KRAS G12C NSCLC is ongoing, as well as different clinical trials are evaluating sotorasib in combination therapies (CodeBreaK101; NCT04185883) with the aim to identify patients who may benefit from sotorasib regimens in the context of first-line treatment (Figure 1). Here, KRAS is linked to non-small cell lung carcinoma.